A

Alnylam Pharmaceuticals

Develops RNAi-based therapies for genetic diseases

Associate Director - Demand & Revenue Forecasting

Corporate Finance & FP&AConfirmed live in the last 24 hours
Full-timeCambridge, MA, USA$162.4k - $219.6k

About the Job

Requirements

  • A bachelor's degree in Engineering, Economics, Statistics, Mathematics, or a related field is required; an MBA, MS, PhD, or other advanced degree is preferred.
  • At least 8 years of pharmaceutical or biotechnology forecasting experience is required.
  • Demonstrated experience in specialty, oncology, or other complex therapeutic areas is required.
  • Experience supporting product launch forecasting is required.
  • Experience using IQVIA, Symphony, MMIT, or similar industry data sources is required.

Responsibilities

  • Develop and oversee comprehensive forecasting models and strategies for the US TTR Franchise.
  • Develop robust forecasting assumptions related to market dynamics, competitive landscape, pricing, payer access, treatment algorithms, and patient flow.
  • Monitor market dynamics, competitor performance, treatment paradigms, payer trends, and regulatory developments that impact forecast performance.
  • Drive forecasting innovation through advanced analytics, predictive modeling, and automation tools.
  • Collaborate with cross-functional teams including marketing, sales, market access, advanced analytics, and supply chain to ensure forecast alignment and accuracy.
  • Present insights to senior executives and cross-functional leadership teams.

Desired Qualifications

  • Familiarity with data visualization and analytics platforms such as Power BI, Tableau, SQL, or R.

About the Company

Alnylam Pharmaceuticals

Develops RNAi-based therapies for genetic diseases

Alnylam Pharmaceuticals develops RNA interference (RNAi) therapeutics to silence disease-causing genes, aiming to treat rare genetic disorders. Its products work by using RNA molecules that block gene expression, reducing the impact of specific genetic diseases. The company differentiates itself by concentrating on RNAi-based drugs for rare diseases and by building a pipeline through large clinical programs and strategic partnerships, such as commercialization deals in the Gulf States and collaborations with investors. Revenue comes from approved drug sales, licensing agreements, strategic collaborations, and related services like genetic testing and counseling. The company’s goal is to advance and commercialize RNAi therapies to improve outcomes for patients with genetic disorders, expanding its portfolio through partnerships and investments.

Company size
1,001-5,000
Company stage
IPO
Headquarters
Cambridge, MA
Founded
2002

Recently Posted Jobs

Explore more opportunities at Alnylam Pharmaceuticals

See more jobs